glp-1 lawsuits news Ozempic Lawsuit: July 2026 Blindness and Gastroparesis Claims Novo Nordisk sues Eli Lilly

Feel free to give us a call at (866) 279-2111

The new label for Ozempic is based on the results of the FLOW trial, which showed a statistically significant reduction in kidney disease progression, as well as cardiovascular and kidney death with a 1 mg/kg weekly dose of the injectable drug compared to placebo

(PubMed) Reduced Inflammation: Investigate how this peptide can manage and reduce inflammation, offering crucial data for chronic conditions and injury recovery

It is commonly explored for its potential role in supporting skin appearance, collagen-related pathways, antioxidant activity, and overall skin wellness